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Moderate sedationAbstract Background: Recently dexmedetomidine had been successfully used in conscious (mod-
erate) sedation as a good competitive to popular agent (midazolam). Different concentrations of
ketamine and propofol combinations (ketofol) were used for procedural sedation and analgesia.
Objectives: The study was conducted to compare two techniques of moderate sedation for patients
undergoing ERCP, using either dexmedetomidine or ketofol as regards hemodynamic, sedation,
pain, respiratory effect, recovery time, patients’ and endoscopists’ satisfactions, and complications
during and after the procedure.
Patients and methods: Fifty patients were randomly allocated in one of two groups; dexmedetom-
idine group D (n= 25) received 1 lg/kg i.v. bolus over 10 min followed by 0.5 lg/kg/h or ketamine/
propofol (ketofol) group KP (n= 25) received 1 mg/kg i.v. bolus followed by 50 lg/kg/min. The
level of sedation was adjusted to achieve a Ramasy sedation scale (RSS) score of 4 in both groups
of patients. Mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation (SPO2),
and facial pain score (FPS) were compared. Time to achieve RSS, modiﬁed Aldrete’s score (MAS)
of 9–10 and the related complications were compared between groups. Patients’ and endoscopists’
satisfactions were compared. Total amount of rescue sedation was recorded.
16 H.I. Eldesuky Ali HassanResults: After loading dose HR and MAP were signiﬁcantly lower in group D as compared with
group KP (p< 0.05). HR was signiﬁcantly lower in group D during the recovery (p< 0.05). No
signiﬁcant difference between both groups as regards time to achieve RSS, MAS, FPS and total
dose of rescue sedation. Personnel restraint was signiﬁcantly lower in group KP (8% versus
20%) than in group D. Endoscopists’ satisfaction was signiﬁcantly higher in group KP than D
group (92% and 80%) respectively.
Conclusion: Ketofol (1:1) provided better hemodynamic stability than dexmedetomidine and stan-
dard alternative to it in moderate sedation during ERCP.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
There were many challenges during moderate sedation for
ERCP in endoscopy unit; as remote location, less familiar
area, semi prone position, lengthy procedure and shared air-
way. It should ensure immobility, sufﬁcient analgesia, avoid
coughing or gagging and allow patient comfort to avoid any
complication as perforation or peritonitis [1]. Moderate seda-
tion sufﬁcient dose should not suppress the airway protective
reﬂexes and monitoring methods should be administered [2].
ERCP (diagnostic or therapeutic) was complicated and lengthy
procedure. It needed moderate, deep sedation, and even gen-
eral anesthesia. The level of sedation as well as the choice of
sedative based on type of procedure and patient characteris-
tics. Diagnostic ERCP procedures involving bile or pancreatic
duct as papillotomy, and dilation of ampulla of vater needed
for moderate sedation/analgesia but more complicated and
lengthy procedure as lithotripsy, stone removal and implanta-
tion of the stent needed for deep sedation and even general
anesthesia (GA) . Patient selection according to ASA classiﬁ-
cation and the history of long term used narcotics, benzodiaze-
pines or any neuropsychiatric medications are very important
in choosing the sedative agent and the level of sedation [3]. In
patients receiving moderate sedation during ERCP, pain and
discomfort during and immediately after ERCP were experi-
enced by one third to one half of the patients due to inade-
quate level of sedation, as well as inadequate selection of
sedative agent against type of procedure and patient physical
and mental status. Incremental doses of midazolam lead to
unintended deep level of sedation as well as hypotension and
desaturation [4]. There was higher failure rate due to prema-
ture termination of ERCP because of inadequate sedation
[5]. There were many trials to improve the patient’s comfort
and the safety. General anesthesia outside the operating room
had cost burden and increased risk of complication and still
remained controversial [6]. Dexmedetomidine is a highly selec-
tive a2 agonist that has sedative, analgesic, anxiolytic, and
amnesic effects without a signiﬁcant respiratory depression
[7]. It displays a dose-dependent blood pressure response. It
has a sympatholytic effect through decreasing the concentra-
tion of norepinephrine which in turn decreases the heart rate
and blood pressure [8]. Ketamine is an NMDA receptor antag-
onist and has also been found to bind to opioid and sigma
receptors. It is phencyclidine derivatives and is classiﬁed as a
dissociative sedation with fairly rapid onset and duration with
little or no respiratory and cardiovascular depression. It causes
amnesia and analgesia but its use as a single sedative agent has
been limited because of its emergence reactions [9]. Propofol isnon-opioid, non-barbiturate, popular sedative, hypnotic agent
with rapid onset, short duration of action. It has undesirable
side effects as cardiovascular and respiratory depressions
which need cardiopulmonary support [10]. The combination
of ketamine and propofol (ketofol) with low doses of each
appeared with a better hemodynamic and respiratory stability.
Ketofol is physically compatible and chemically stable and it
can be stored at room temperature and under light [11,12].
Ketamine is adding analgesia to propofol sedation, while vom-
iting and hallucination induced by ketamine are countered by
propofol antiemetic and hypnotic properties [13]. There was a
single study on the use of ketofol for moderate sedation in
ERCP but with different concentration of ketofol [14]. The
aim of the study was to compare between two regimens of
moderate sedation; dexmedetomidine versus ketofol in ERCP
as regards hemodynamic, sedation, pain, respiratory effect,
recovery time, patients’ and endoscopists’ satisfactions, and
complications during and after the procedure.
2. Patients and methods
A prospective double-blind randomized study was carried out
in King Abdul-Aziz hospital, Saudi Arabia; March 2013 to
March 2014. Approval of ethical committee and written
informed consents from patients were obtained. Patients
scheduled for elective diagnostic and therapeutic ERCP. The
study enrolled 50 patients were ASA physical classiﬁcations I
and II, aged 18–60 years, and from both sexes. We excluded
patients who had ASA physical statuses III and IV, allergy
to any drug used in the study, history of sedative and narcotic
analgesic drugs, cardiovascular diseases as hypertension,
mitral stenosis, aortic stenosis, arrhythmia, or congestive heart
failure, liver or renal insufﬁciency, diabetes, seizures, preg-
nancy, and morbid obese or uncooperative patient. Preopera-
tive assessment including general, systemic examination, and
routine laboratory investigation was done. Patients were ran-
domly allocated by the ‘‘sealed envelope technique’’ to one
of two groups by 1:1 ratio. They received either of the follow-
ing two regimens: dexmedetomidine group D (n= 25) or keto-
fol group KP (n= 25). On arrival in endoscopy unit the sealed
envelope opened and the written regimen applied. Antecubital
venous access secured on nondominant hand by 20 G intrave-
nous cannula, ringer lactate drip started by 8 ml/kg/h and
nasal cannula by 4 L/min o2. Basal HR, MAP, and spo2 were
recorded. The study drugs were prepared by an assistant who
was not involved in the study. He covered all syringes and infu-
sion sets by silver paper due to different colors. Both bolus and
maintenance doses were given using syringe pump (Abbott-life
Table 1 Ramsay Sedation Scale.
1 Patient is anxious and agitated or restless, or both
2 Patient is co-operative, oriented, and tranquil
3 Patient responds to commands only
4 Patient exhibits brisk response to light glabellar tap or loud
auditory stimulus
5 Patient exhibits a sluggish response to light glabellar tap or loud
auditory stimulus
6 Patient exhibits no response
Dexmedetomidine versus ketofol 17care 5000). The groups were similar in respect to time of pro-
cedure by the same endoscopist. For dexmedetomidine group
D; (Precedex 200 lg/2 ml; Abbott) which prepared as 2 ml
Precedex plus 18 ml normal saline total volume 20 ml
(1 ml = 10 lg Precedex); patients received loading dose of
1 lg/kg i.v. over 10 min followed by 0.5 lg/kg/h infusion until
achieving RSS of 4. In ketofol group KP; patients received
ketofol which prepared as 2 ml ketamine (50 mg/ml) and
10 ml propofol 1% (10 mg/ml) plus 8 ml normal saline. The
mixture was 20 ml by 1:1 and each ml contained 5 mg for ket-
amine and 5 mg for propofol. Patients received 1 mg/kg over
10 min and followed by 50 lg/kg/min till achieving RSS of 4
(Table 1). The level of sedation assessed at 1–3 min interval
and the infusion rate adjusted to achieve RSS of 4. The anes-
thesiologist who gave the drugs and assessed parameters was
blinded to the randomization process and to the drugs of study
but he can adjust the infusion rate till achieving RSS of 4.
Adjustment of group D was 0.1–0.2 lg/kg/h and for group
KP was 25 lg/kg/min. Dexmedetomidine 20 ml syringe was
labeled as bolus and infusion 1 and ketofol 20 ml syringe
was labeled as bolus and infusion 2. Time to achieve RSS of
4 in both groups was recorded. HR, MAP, and SpO2 were also
recorded following the loading dose and every 5 min until
completion of the procedure. The FPS (0–10) to evaluate pain
at 5 min interval during the procedure (Fig. 1) and in the
recovery till MAS reached 9–10 (Table 2). During the proce-
dure if patient required personnel restraint, either patient or
endoscopist was uncomfortable or FPS more than 5, the rescue
IV sedation was provided with propofol in top up increment
dose of 10 mg and total dose was recorded. During the proce-
dure, any of the following complications were noted, recorded
and treated accordingly: oxygen desaturation was considered
when SpO2 less than 92% for more than 10 s. Apnea was
deﬁned as not having a spontaneous breathing for at least
20 s. Both were managed by supporting airway and/or assist-
ing ventilation. Bradycardia was considered when HR was less
than 60 beats/min and managed with atropine 20 mcg/kg i.v.
Hypotension was considered when MAP decreased byFigure 1 Facia>20% of the baseline MAP and managed by ﬂuid bolus or
vasopressors. Any cough or gagging was noted and recorded.
The study drug infusion discontinued at the end of the proce-
dure. During the recovery, the recovery nurse was blinded to
study medication and the following parameters were recorded:
the recovery time was considered from discontinuation of the
infusion till achieving MAS 9-10 and during that time HR,
MAP, and SpO2 were recorded at 5 min interval. Postoperative
nausea and vomiting (PONV), apnea, pain and agitation were
recorded and managed accordingly. Patients’ and endosco-
pists’ satisfactions were assessed using satisfaction score
(4 = excellent, 3 = good, 2 = fair, and 1 = bad). Patient
and endoscopist considered satisﬁed with good and excellent
scores and % of satisfaction was calculated in both groups.
3. Statistical analysis
A power analysis for sample size suggested a minimum 24
patients in each group with a mean of 94.4 mm Hg of MAP
in group PK, and 75.5 mm Hg of MAP in group D and SD
2.7 with (a= 0.05) gave statistical power 98.8%. We included
50 patients in both groups in the study. Data were statistically
described in terms of mean ± standard deviation (±SD), or
frequencies (number of cases) and percentages when appropri-
ate. Numerical data between both groups were done using Stu-
dent’s t-test for independent samples. Categorical data were
compared by Chi-square test. P values less than 0.05 were con-
sidered statistically signiﬁcant. All statistical calculations were
done using computer programs SPSS (Statistical Package for
the Social Science; SPSS Inc., Chicago, IL, USA) version 15
for Microsoft Windows.
4. Results
There were no signiﬁcant differences in either the demographic
data, duration of the procedure or total doses of rescue seda-
tion (propofol) between the two groups. (Table 3). There were
no signiﬁcant differences in either preoperative or recovery
vital signs except patients in group D had statistically signiﬁ-
cant (P< 0.05) lower HR (74 ± 4.3 beat/min) and slight
tachycardia (91.3 ± 7.9 beat/min) in group KP during recov-
ery (Table 4). Total dose of ketamine or propofol in ketofol
used during the procedure was (130 ± 0.5 mg) of each. There
was no increment dose used in both groups. Total doses of res-
cue sedation of propofol were 27.2 ± 1.7 and 24.5 ± 2.8 mg in
group D and KP respectively with no signiﬁcant difference
between both groups p> 0.05.
Patients in group D had statistically signiﬁcant (P< 0.05)
lower HR and MAP after the loading dose at 5, 10, 15, 20, 25,l pain score.
Table 3 Demographic characteristic, duration of procedure and total dose of rescue sedation.
Variable Group D (n= 25) Group KP (n= 25) P value
Age (years) 37.4 ± 12.3 37.04 ± 11.8 0.916
Weight (kg) 77.64 ± 8.9 77.46 ± 8.6 0.942
Sex (M/F) 15/10 14/11
ASA classiﬁcation (I, %) 16 (64%) 17 (68%)
Duration of procedure (min) 47.5 ± 1.8 48.5 ± 1.5 0.378
Total dose of propofol as rescue sedation (mg) 27.2 ± 1.7 24.5 ± 2.8 0.12
Data were expressed as mean ± SD. P value > 0.05 was considered statistically not signiﬁcant. * P value < 0.05 was considered statistically
signiﬁcant. Group D; dexmedetomidine group, group KP; ketofol group.
Table 4 Vital signs preoperative and during recovery.
Variable Group D (n= 25) Group KP (n= 25) P value
Preoperative:
HR (beat/min) 79.5 ± 4.9 78.2 ± 4.5 0.333
MAP (mm Hg) 89.4 ± 5 87.6 ± 4.1 0.17
SpO2 (%) 97.6 ± 0.9 97.7 ± 0.7 0.663
During recovery:
HR(beat/min) 74 ± 4.3 91.3 ± 7.9 0.0001
MAP(mm Hg) 88 ± 5.1 87.6 ± 5.2 0.785
SpO2 (%) 98.2 ± 0.9 98.4 ± 0.8 0.41
Data were expressed as mean ± SD. P value > 0.05 was considered statistically not signiﬁcant. P value < 0.05 was considered statistically
signiﬁcant. Group D; dexmedetomidine group, group KP; ketofol group.
Table 2 Modiﬁed Aldrete’s score.
Parameter Score
2 1 0
Activity Moves all extremities voluntarily
or on command
Moves two extremities voluntarily or
on command
Unable to move extremities
Respiration Breathes deeply and coughs
freely
Dyspnea, shallow or limited
breathing
Apneic
Circulation BP ± 20 mm of preanesthetic
level
Bp ± 20–50 mm of preanesthetic
level
BP ± 50 mm of
preanesthetic level
Consciousness Fully awake Arousable on calling Not responding
Oxygen saturation SpO2 > 92% on room air Supplemental O2 required to
maintain SpO2 > 90%
SpO2 < 90% with O2
supplementation
Total score = 10; a score ofP 9 required for discharge.
18 H.I. Eldesuky Ali Hassanand 30 min during ERCP procedure (Tables 5 and 6). There
were no signiﬁcant differences in SpO2. The time to achieve
RSS (12.4 ± 1.1 min) and (13.2 ± 0.5 min) or the time to
achieve MASP 9 (11.4 ± 0.5) min and (12.5 ± 1.8 min) with
(p> 0.05) between both groups respectively (Table 7) .
Patients in group D showed higher incidence of restlessness
(restraint) than group KP (8%) and (4%) respectively but
patients in group KP showed higher incidences of PONV
(16%) and agitation (8%) as compared with group D (8%)
and (0%) respectively (Table 8). Both groups had similar
FPS (p> 0.05) during ERCP and recovery (Fig. 2). Both
patients’ and endoscopists’ satisfaction scores were higher in
group KP (92% and 92%) as compared with group D (88%
and 80%) with (P> 0.05) and (p< 0.05) respectively
(Table 9).5. Discussion
The goals of the conducted study were to provide adequate
steady state of sedation level while maintaining airway reﬂex,
maintain cardiovascular and respiratory status, minimize side
effects and pain and ensure patient comfort [15]. The current
study compared the efﬁcacy and safety of two different regi-
mens of moderate sedation. The dose of dexmedetomidine used
in the study was similar to previous study [16]. The ketofol dose
was different and new to other studies which investigated the
best admixture dose. The most of studies used ketofol as induc-
tion agent for short procedures or in deep sedation but no study
used it in moderate sedation. They concluded that combination
4:1 of propofol/ketamine contributed adequate deep sedation
and analgesia without hemodynamic and respiratory
Table 5 Changes of HR between both groups during the
procedure.
Variable (min) Group D N= 25 Group KP N= 25 P value
5 75.5 ± 1.05 92.2 ± 4.8 0.0001
10 76.7 ± 1.6 87.2 ± 3.3 0.0001
15 77 ± 1.5 86.6 ± 3.7 0.0001
20 75.5 ± 1.05 86 ± 3.5 0.0001
25 75.1 ± 2.3 93.8 ± 5.3 0.0001
30 75 ± 2 86 ± 3.9 0.0001
Values presented by numbers, means and standard deviations.
P< 0.05 was statistically signiﬁcant. Group D; dexmedetomidine
group, KP group; ketofol group.
Table 6 Changes of MAP between both groups during the
procedure.
Variable (min) Group D N= 25 Group KP N= 25 P value
5 75.5 ± 0.8 94.4 ± 2.7 0.0001
10 76.5 ± 1.3 92.5 ± 1.5 0.0001
15 73.6 ± 2.1 95.5 ± 3.2 0.0001
20 70.8 ± 2.6 93.2 ± 3.6 0.0001
25 75.1 ± 2.7 93.6 ± 3.6 0.0001
30 76.8 ± 1.1 92 ± 1.5 0.0001
Values presented by numbers, means and standard deviations.
P< 0.05 was statistically signiﬁcant. Group D; dexmedetomidine
group, group KP; ketofol group.
Table 7 Time to achieve RSS and MAS.
Variable Group D Group KP P value
Time to RSS (min) 12.4 ± 1.1 13.2 ± 0.5 0.44
Time to MAS (min) 11.4 ± 0.5 12.5 ± 1.8 0.23
Data were expressed as mean ± SD. P value > 0.05 was consid-
ered statistically not signiﬁcant. * P value < 0.05 was considered
statistically signiﬁcant. Group D; dexmedetomidine, Group KP;
ketofol group, RSS; Ramasy sedation score, MAS; modiﬁed
Aldrete’s score.
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Figure 2 FPS during the procedure and recovery.
Dexmedetomidine versus ketofol 19depression or psychotomimetic side effects [17]. The current
study used ketofol admixture 1:1 and continuous infusion to
maintain adequate moderate sedation which monitored byTable 8 Complications during the procedure and recovery.
Variable Group D (n= 25)
During the procedure:
Apnea 0
Cough 0
Gagging 0
Restraint (n, %) 2/25 (8%)
During recovery:
PONV 2/25 (8%)
Apnea 0
Agitation 0
Data were expressed as mean ± SD. P value > 0.05 was considered stat
signiﬁcant. Group D; dexmedetomidine group, group KP; ketofol groupRSS. In our study there was no event of hypotension or brady-
cardia observed in both regimens. Patients in group D showed
lower HR and MAP and these results were in accordance with
previous studies [16,18]. Patients in ketofol group showed more
stability in HR andMAP because propofol/ketamine combina-
tion was thought to act by antagonizing the side effect which
was consistent with previous study [19]. They concluded that
minimal changes observed inMAP andHRmay be dose related
and because sympathomimetic action of ketamine was effective
in countered action of the hemodynamic depression of propofol
and there was no occurrence of profound tachycardia or brady-
cardia in any group. These ﬁndings suggested that ketofol had
clinical advantages over dexmedetomidine as regards
controlling hemodynamic variability. In the current study there
was no event of apnea or desaturation in both groups which
matched with previous trials for both dexmedetomidine and
ketofol [20,16]. In current study there was slight longer
time to achieve RSS of 4 in group KP than group D
(13.2 ± 0.5 min and 12.4 ± 1.1 min respectively) but it was still
in the acceptable range and due to slow onset of action of ket-
amine. These results matched with previous study which com-
pared ketofol with ketamine for sedation time and found that
ketamine had 16 min sedation time versus 13 min for ketofol
[21]. In our study the recovery time of groupDwas shorter than
group KP (11.4 ± 0.5 min and 12.5 ± 1.8 min respectively)
and this was accepted. Slower clearance of ketamine was prob-
ably responsible for this [19]. We used FPS for pain assessment
during sedation because there was difﬁculty to communicate or
ask the patient about pain score during sedation sowe dependedGroup KP (n= 25) P value
0 –
0 –
0 –
1/25 (4%) P> 0.05
4/25 (16%) P> 0.05
0
2/25 (8%) p> 0.05
istically not signiﬁcant. * P value < 0.05 was considered statistically
.
Table 9 Patients’ and endoscopists’ satisfactions score.
Variable Group D (n= 25) Group KP (n= 25) P value
Patients’ satisfaction (n/%) 22/(88%) 23/(92%) P> 0.05
Endoscopist’ satisfaction (n/%) 20/(80%) 23/(92%) P< 0.05*
Data were expressed as mean ± SD. P value > 0.05 was considered statistically not signiﬁcant.
* P value < 0.05 was considered statistically signiﬁcant. Group D; dexmedetomidine group, group KP; ketofol group.
20 H.I. Eldesuky Ali Hassanon patient’s face expressions. We also used it during the recov-
ery because some patients were uncooperative to use VAS and
they did not understand it. Both sedation drugs in our study
provided low FPS during procedure and recovery. The rescue
sedation of propofol was given only to reduce movement and
personnel restraints with no statistical signiﬁcant differences
between both groups as regards rescue sedation or personnel
restraints and there was no rescue analgesic in both groups.
These results matched with Rapeport et al. who found ketofol
1:1 infusion used in conjunction with regional anesthesia was
safe and effective in high risk patients and provided adequate
sedation [22]. In the recovery four patients (16%) in ketofol
group showed PONV and emergence reactions by (8%)
and these results accepted with higher dose of ketamine
(112 ± 0.5 mg) which was countered acted by antiemetic and
sedative effects of propofol and still lower than incidence rate
of ketamine alone. Emergence reactions were 50% in adults
which had been reported by others [23–25]. In the current study
ketofol group had higher satisfaction scores of both patients
and endoscopist. Our ﬁndings mismatched with Dere et al.
results [26]. They found high satisfaction for dexmedetomidine
when compared with midazolam. Our ﬁndings were most prob-
ably due to fewer personnel restraints in ketofol group versus
group D (4% versus 8%) respectively. Many studies compared
dexmedetomidine versus midazolam in ERCP or colonoscopy
[26,27]. They concluded that it was more efﬁcient in hemody-
namic and respiratory status with high satisfaction scores. We
concluded that in our study but with less satisfaction scores.
Andolfatto et al. used ketofol mixture (1:1) for emergency pro-
cedural sedation and analgesia by low dose ketamine 0.25 mg/
kg and they found adequate sedation, relative high pain score
and low unpleasant emergence [2]. It explained by low dose of
ketamine which provided less analgesia. In our study increased
ketamine dose provided adequate analgesia and also still lower
unpleasant emergence. Weatheral et al. used ketofol (1:1) by
1 mg/kg with regional anesthesia for orthopedic procedure
and they found good safety margin for this combination with
no episode of cardiovascular or respiratory compromise was
documented [28]. We used combination to add synergism and
decrease unwanted side effects. Ketofol as a combination asso-
ciated with improved hemodynamic when compared to stan-
dard midazolam, fentanyl or even dexmedetomidine sedation.
Ketofol had been proved to be safe, effective and reliable in
adults and children [29]. Tosun et al. compared propofol
1.2 mg/kg and ketamine 1 mg/kg in ratio 1.2:1 versus propo-
fol/fentanyl in the same ratio and both combinations provided
effective sedation and analgesia during dressing changes in
burnt patients in agreement with our results [30]. Our results
suggested that our combination propofol/ketamine 1:1 was
more suitable inmoderate sedation during ERCP (all diagnostic
and therapeutic as stone removal and stent implantation). We
used ketofol and dexmedetomidine by adjusted doses to ensure
moderate level of sedation without affecting the hemodynamicand respiration. We used ketofol to ensure moderate sedation
without unintended deep level of sedation to avoid its complica-
tion outside OR. The doses of two drugs were suitable in mod-
erate sedation and effective in diagnostic and even some
therapeutic ERCP with good selection of the patients to ensure
safety.
6. Conclusion
Propofol/ketamine (1:1) bolus and modiﬁed infusion rate pro-
vided adequate sedation, with hemodynamic and respiratory
stability, and accepted few side effects. It appeared to be safe
with higher satisfaction scores for patients and endoscopists.
It was a good competitive to standard sedative as dexmede-
tomidine in moderate sedation during ERCP.
7. Limitations of this study
The blinded study was difﬁcult due to different colors of med-
ications but it solved by sliver paper. The study included small
group of patients but it was according to the sample size calcu-
lation. Further studies needed to increase the number of
patients with the different concentrations of ketofol.
Conﬂict of Interest
We have no conﬂict of interest to declare.
References
[1] Lichtenstein DR, Jagannath S, Baron TH, Anderson MA,
Banerjee S, Dominitz JA, et al. Sedation and anesthesia in GI
endoscopy. Gastrointest Endosc 2008;68(5):815–26.
[2] Demiraran Y, Korkut E, Tamer A, Ilknur Y, Buket K, Gulbin
S, et al. The comparison of dexmedetomidine and midazolam
used for sedation of patients under upper endoscopy: a
prospective, randomized study. Can J Gastroenterol
2007;21:25–9.
[3] Paspatis GA, Tribonias G, Paraskeva K. Level of intended
sedation. Digestion 2010;82:84–6.
[4] Jeurnink SM, Steyerberg E, Kuipers E, Siersema P. The burden
of endoscopic retrograde cholangiopancreatography (ERCP)
performed with the patient under conscious sedation. Surg
Endosc 2012;26:2213–9.
[5] Raymondos K, Panning B, Bachem I, Manns MP, Piepenbrock
S, Meier PN. Evaluation of endoscopic retrograde
cholangiopancreatography under conscious sedation and
general anesthesia. Endoscopy 2002;34:721–6.
[6] Cook T, Behringer EC, Benger J. Airway management outside
the operating room: hazardous and incompletely studied. Curr
Opin Anaesthesiol 2012;25:461–9.
[7] Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine:
a review of clinical applications. Curr Opin Anaesthesiol
2008;21:457–61.
Dexmedetomidine versus ketofol 21[8] Paris A, Tonner PH. Dexmedetomidine in anesthesia. Curr Opin
Anaesthesiol 2005;18:412–8.
[9] Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events
associated with procedural sedation and analgesia in a pediatric
emergency department: a comparison of parenteral drugs. Acad
Emerg Med 2005;12:508–13.
[10] Cote´ GA, Hovis RM, Ansstas MA, Waldbaum L, Azar RR,
Early DS, et al. Incidence of sedation-related complications
with propofol use during advanced endoscopic procedures. Clin
Gastroen Hepatol 2010;8:137–42.
[11] Morse Z, Sano K, Kanri T. Effect of propofol-ketamine
admixture in human volunteers. Pac Health Dialog
2003;10:51–4.
[12] Trissel LA, Gildert DL, Martinez JF. Compatibility of propofol
emulsion with selected drugs during simulated Y – site
administration. Am J Health Syst Pharm 1997;54:1287–92.
[13] Willman E, Andolfatto G. A prospective evaluation of ketofol
for procedural sedation and analgesia in the emergency
department. Ann Emerg Med 2013;49:23–30.
[14] Riham H, Wael ES. Ketamine/propofol versus fentanyl/
propofol for sedating obese patients undergoing endoscopic
retrograde cholangiopancreatography (ERCP). Egypt J Anesth
2013;29:207–11.
[15] Aouad MT, Moussa AR, Dagher CM. Addition of ketamine to
propofol for initiation of procedural anesthesia in children
reduces propofol consumption and preserves hemodynamic
stability. Acta Anaesthesiol Scand 2008;52:561–5.
[16] Kilic N, Sahin S, Aksu H, Yavascaoglu B. Conscious sedation
for endoscopic retrograde cholangiopancreatography:
dexmedetomidine versus midazolam. Eurasian J Med
2011;43:13–7.
[17] Daabis M, Elsherbiny M, Alotibi R. Assessment of different
concentration of ketofol in procedural operation. BMJ
2009;2(1):27–31.
[18] Alhashemi JA. Dexmedetomidine vs. midazolam for monitored
anesthesia care during cataract surgery. Br J Anaesth
2006;96:722–6.
[19] Akin A, Esmaoglu A, Guler G, Demircioglu R, Narin N, Boyaci
A. Propofol and propofol/ketamine in pediatric patients
undergoing cardiac catheterization. Pediatr Cardiol
2005;26:553–7.[20] Arain SR, Ebert TJ. The efﬁcacy, side effects, and recovery
characteristics of dexmedetomidine versus propofol when used
for intraoperative sedation. Anesth Analg 2002;95:461–6.
[21] Shah A, Mosdossy G, McLeod S, Lehnhardt K, Peddle M,
Rieder M. A blinded, randomized controlled trial to evaluate
ketamine/propofol versus ketamine alone for procedural
sedation in children. Ann Emerg Med 2011;57(5):425–33.
[22] Rapeport DA, Martyr JW, Wang LP. The use of ketofol
(Ketamine/propofol admixture) infusion in conjunction with
regional anesthesia. Anesth Intens Care 2009;37(1):121–3.
[23] Willman EV, Andolfatto G. A prospective evaluation of
‘‘ketofol’’ (ketamine/propofol combination) for procedural
sedation and analgesia in the emergency department. Ann
Emerg Med 2007;49:23–30.
[24] Green SM, Krauss B. Clinical practice guideline for emergency
department ketamine dissociative sedation in children. Ann
Emerg Med 2004;44:460–71.
[25] Chudnofsky CR, Weber JE, Stoyanoff PJ, Colone PD,
Wilkerson MD, Hallinen DL, et al. A combination of
midazolam and ketamine for procedural sedation and
analgesia in adult emergency department patients. Acad
Emerg Med 2000;7:228–35.
[26] Dere K, Sucullu I, Budak ET, Yeyen S, Filiz AI, Ozkan S, et al.
A comparison of dexmedetomidine versus midazolam for
sedation, pain and hemodynamic control, during colonoscopy
under conscious sedation. Eur J Anaesthesiol 2010;27:648–52.
[27] Sethi P, Sadik M, Kumar P, Gupta N. Dexmedetomidine versus
midazolam for conscious sedation in endoscopic retrograde
cholangiopancreatography: an open-label randomized
controlled trial. Indian J Anesth 2014;58(1):18–24.
[28] Weatherall A, Venclovas R. Experience with a propofol/
Ketamine mixture for sedation during pediatric orthopedic
surgery. Paediatr Anaesth 2012;20(11):1009–16.
[29] Smischney N, Beach M, Loftus R, Dodds TM, Koff MD.
Ketamine/propofol admixture (ketofol) is associated with
improved hemodynamics as an induction agent: a randomized,
controlled trial. J Trauma Acute Surg 2012;73(1):94–101.
[30] Tosun Z, Esmaoglu A, Coruh A. Propofol–ketamine vs
propofol–fentanyl combinations for deep sedation and
analgesia in pediatric patients undergoing burn dressing
changes. Pediatr Anesth 2008;18:43–7.
